nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—NR3C2—Betamethasone—psoriasis	0.189	0.252	CbGbCtD
Nimodipine—NR3C2—Prednisolone—psoriasis	0.187	0.249	CbGbCtD
Nimodipine—NR3C2—Dexamethasone—psoriasis	0.11	0.147	CbGbCtD
Nimodipine—CYP3A5—Beclomethasone—psoriasis	0.0655	0.0872	CbGbCtD
Nimodipine—CACNA1S—pes—psoriasis	0.0317	0.696	CbGeAlD
Nimodipine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0261	0.0347	CbGbCtD
Nimodipine—CYP3A4—Calcitriol—psoriasis	0.0228	0.0303	CbGbCtD
Nimodipine—CYP3A5—Hydrocortisone—psoriasis	0.0209	0.0279	CbGbCtD
Nimodipine—CYP3A5—Cyclosporine—psoriasis	0.0198	0.0263	CbGbCtD
Nimodipine—CYP3A4—Methoxsalen—psoriasis	0.0177	0.0236	CbGbCtD
Nimodipine—CYP3A5—Dexamethasone—psoriasis	0.013	0.0173	CbGbCtD
Nimodipine—CYP3A4—Cholecalciferol—psoriasis	0.0117	0.0156	CbGbCtD
Nimodipine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0102	0.0135	CbGbCtD
Nimodipine—CYP3A4—Triamcinolone—psoriasis	0.0102	0.0135	CbGbCtD
Nimodipine—CYP3A4—Betamethasone—psoriasis	0.00872	0.0116	CbGbCtD
Nimodipine—CYP3A4—Prednisolone—psoriasis	0.0086	0.0115	CbGbCtD
Nimodipine—CYP3A4—Hydrocortisone—psoriasis	0.00816	0.0109	CbGbCtD
Nimodipine—CYP3A4—Prednisone—psoriasis	0.00813	0.0108	CbGbCtD
Nimodipine—CYP3A4—Cyclosporine—psoriasis	0.0077	0.0103	CbGbCtD
Nimodipine—CYP3A4—Dexamethasone—psoriasis	0.00507	0.00676	CbGbCtD
Nimodipine—NR3C2—ACE Inhibitor Pathway—REN—psoriasis	0.00307	0.0893	CbGpPWpGaD
Nimodipine—CACNB4—tendon—psoriasis	0.00284	0.0623	CbGeAlD
Nimodipine—CACNA1S—tendon—psoriasis	0.00243	0.0533	CbGeAlD
Nimodipine—CACNB1—tendon—psoriasis	0.00227	0.0497	CbGeAlD
Nimodipine—CACNB3—tendon—psoriasis	0.00218	0.0477	CbGeAlD
Nimodipine—NR3C2—ACE Inhibitor Pathway—ACE—psoriasis	0.00191	0.0557	CbGpPWpGaD
Nimodipine—AHR—tendon—psoriasis	0.00161	0.0353	CbGeAlD
Nimodipine—CACNB2—tendon—psoriasis	0.00146	0.032	CbGeAlD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00122	0.0356	CbGpPWpGaD
Nimodipine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00112	0.0326	CbGpPWpGaD
Nimodipine—NR3C2—tendon—psoriasis	0.00107	0.0235	CbGeAlD
Nimodipine—AHR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000922	0.0268	CbGpPWpGaD
Nimodipine—CACNB3—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000837	0.0244	CbGpPWpGaD
Nimodipine—CACNB1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000814	0.0237	CbGpPWpGaD
Nimodipine—CACNA1F—Alzheimers Disease—APOE—psoriasis	0.000688	0.02	CbGpPWpGaD
Nimodipine—NR3C2—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000617	0.018	CbGpPWpGaD
Nimodipine—CACNA1S—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000596	0.0174	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000525	0.0153	CbGpPWpGaD
Nimodipine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000521	0.0152	CbGpPWpGaD
Nimodipine—CACNA1D—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000484	0.0141	CbGpPWpGaD
Nimodipine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000465	0.0135	CbGpPWpGaD
Nimodipine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000459	0.0134	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000454	0.0132	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000437	0.0127	CbGpPWpGaD
Nimodipine—AHR—Adipogenesis—SOCS1—psoriasis	0.000434	0.0126	CbGpPWpGaD
Nimodipine—NR3C2—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00043	0.0125	CbGpPWpGaD
Nimodipine—CACNA1C—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000425	0.0124	CbGpPWpGaD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000417	0.0121	CbGpPWpGaD
Nimodipine—Muscle spasms—Mycophenolic acid—psoriasis	0.0004	0.00237	CcSEcCtD
Nimodipine—Nervous system disorder—Hydroxyurea—psoriasis	0.000398	0.00235	CcSEcCtD
Nimodipine—Hepatobiliary disease—Mycophenolate mofetil—psoriasis	0.000398	0.00235	CcSEcCtD
Nimodipine—Diarrhoea—Calcitriol—psoriasis	0.000398	0.00235	CcSEcCtD
Nimodipine—Thrombocytopenia—Hydroxyurea—psoriasis	0.000397	0.00235	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000397	0.0115	CbGpPWpGaD
Nimodipine—Sweating increased—Triamcinolone—psoriasis	0.000394	0.00233	CcSEcCtD
Nimodipine—Nausea—Methoxsalen—psoriasis	0.000387	0.00229	CcSEcCtD
Nimodipine—Hepatitis—Cyclosporine—psoriasis	0.000387	0.00229	CcSEcCtD
Nimodipine—Anaemia—Mycophenolic acid—psoriasis	0.000385	0.00227	CcSEcCtD
Nimodipine—Bradycardia—Mycophenolate mofetil—psoriasis	0.000384	0.00227	CcSEcCtD
Nimodipine—Hypersensitivity—Acitretin—psoriasis	0.000381	0.00225	CcSEcCtD
Nimodipine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00038	0.00224	CcSEcCtD
Nimodipine—Hepatitis—Mycophenolate mofetil—psoriasis	0.000378	0.00223	CcSEcCtD
Nimodipine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000377	0.011	CbGpPWpGaD
Nimodipine—Gastrointestinal haemorrhage—Prednisone—psoriasis	0.00037	0.00219	CcSEcCtD
Nimodipine—Vomiting—Calcitriol—psoriasis	0.000369	0.00218	CcSEcCtD
Nimodipine—Palpitations—Mycophenolic acid—psoriasis	0.000368	0.00217	CcSEcCtD
Nimodipine—Rash—Calcitriol—psoriasis	0.000366	0.00216	CcSEcCtD
Nimodipine—Dermatitis—Calcitriol—psoriasis	0.000366	0.00216	CcSEcCtD
Nimodipine—Pruritus—Acitretin—psoriasis	0.000366	0.00216	CcSEcCtD
Nimodipine—Pruritus—Fluocinolone Acetonide—psoriasis	0.000365	0.00216	CcSEcCtD
Nimodipine—Headache—Calcitriol—psoriasis	0.000364	0.00215	CcSEcCtD
Nimodipine—Dyspnoea—Hydroxyurea—psoriasis	0.000362	0.00214	CcSEcCtD
Nimodipine—Hypertension—Mycophenolic acid—psoriasis	0.00036	0.00212	CcSEcCtD
Nimodipine—Flushing—Cyclosporine—psoriasis	0.000359	0.00212	CcSEcCtD
Nimodipine—Bradycardia—Prednisolone—psoriasis	0.000359	0.00212	CcSEcCtD
Nimodipine—Sweating increased—Betamethasone—psoriasis	0.000358	0.00211	CcSEcCtD
Nimodipine—Sweating increased—Dexamethasone—psoriasis	0.000358	0.00211	CcSEcCtD
Nimodipine—Myalgia—Mycophenolic acid—psoriasis	0.000355	0.0021	CcSEcCtD
Nimodipine—Diarrhoea—Acitretin—psoriasis	0.000354	0.00209	CcSEcCtD
Nimodipine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000353	0.00208	CcSEcCtD
Nimodipine—Angiopathy—Cyclosporine—psoriasis	0.000351	0.00208	CcSEcCtD
Nimodipine—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.00035	0.00207	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00035	0.00207	CcSEcCtD
Nimodipine—Bradycardia—Hydrocortisone—psoriasis	0.00035	0.00207	CcSEcCtD
Nimodipine—Nausea—Calcitriol—psoriasis	0.000345	0.00204	CcSEcCtD
Nimodipine—Angiopathy—Mycophenolate mofetil—psoriasis	0.000343	0.00202	CcSEcCtD
Nimodipine—Dizziness—Acitretin—psoriasis	0.000342	0.00202	CcSEcCtD
Nimodipine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000341	0.00201	CcSEcCtD
Nimodipine—Oedema—Mycophenolic acid—psoriasis	0.00034	0.00201	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.00034	0.00989	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.00034	0.00989	CbGpPWpGaD
Nimodipine—Nervous system disorder—Mycophenolic acid—psoriasis	0.000333	0.00197	CcSEcCtD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000333	0.0097	CbGpPWpGaD
Nimodipine—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000333	0.00197	CcSEcCtD
Nimodipine—Tachycardia—Mycophenolic acid—psoriasis	0.000332	0.00196	CcSEcCtD
Nimodipine—Bradycardia—Triamcinolone—psoriasis	0.00033	0.00195	CcSEcCtD
Nimodipine—Vomiting—Acitretin—psoriasis	0.000329	0.00194	CcSEcCtD
Nimodipine—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000329	0.00194	CcSEcCtD
Nimodipine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000328	0.00194	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Prednisone—psoriasis	0.000326	0.00193	CcSEcCtD
Nimodipine—Rash—Acitretin—psoriasis	0.000326	0.00193	CcSEcCtD
Nimodipine—Dermatitis—Acitretin—psoriasis	0.000326	0.00192	CcSEcCtD
Nimodipine—Rash—Fluocinolone Acetonide—psoriasis	0.000325	0.00192	CcSEcCtD
Nimodipine—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000325	0.00192	CcSEcCtD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000324	0.00944	CbGpPWpGaD
Nimodipine—Muscle spasms—Cyclosporine—psoriasis	0.000324	0.00191	CcSEcCtD
Nimodipine—Headache—Acitretin—psoriasis	0.000324	0.00191	CcSEcCtD
Nimodipine—Headache—Fluocinolone Acetonide—psoriasis	0.000323	0.00191	CcSEcCtD
Nimodipine—AHR—Adipogenesis—LEP—psoriasis	0.00032	0.00932	CbGpPWpGaD
Nimodipine—CACNA1F—Alzheimers Disease—TNF—psoriasis	0.000318	0.00926	CbGpPWpGaD
Nimodipine—Hypotension—Mycophenolic acid—psoriasis	0.000318	0.00188	CcSEcCtD
Nimodipine—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000316	0.00187	CcSEcCtD
Nimodipine—Sweating increased—Prednisone—psoriasis	0.000311	0.00184	CcSEcCtD
Nimodipine—Anaemia—Cyclosporine—psoriasis	0.000311	0.00184	CcSEcCtD
Nimodipine—Immune system disorder—Hydrocortisone—psoriasis	0.000311	0.00184	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00031	0.00183	CcSEcCtD
Nimodipine—Nausea—Acitretin—psoriasis	0.000307	0.00181	CcSEcCtD
Nimodipine—Nausea—Fluocinolone Acetonide—psoriasis	0.000306	0.00181	CcSEcCtD
Nimodipine—Anaemia—Mycophenolate mofetil—psoriasis	0.000304	0.0018	CcSEcCtD
Nimodipine—Dyspnoea—Mycophenolic acid—psoriasis	0.000303	0.00179	CcSEcCtD
Nimodipine—Bradycardia—Betamethasone—psoriasis	0.000299	0.00177	CcSEcCtD
Nimodipine—Bradycardia—Dexamethasone—psoriasis	0.000299	0.00177	CcSEcCtD
Nimodipine—Hypersensitivity—Hydroxyurea—psoriasis	0.000299	0.00177	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000293	0.00173	CcSEcCtD
Nimodipine—Hypertension—Cyclosporine—psoriasis	0.000291	0.00172	CcSEcCtD
Nimodipine—Palpitations—Mycophenolate mofetil—psoriasis	0.00029	0.00172	CcSEcCtD
Nimodipine—Myalgia—Cyclosporine—psoriasis	0.000287	0.0017	CcSEcCtD
Nimodipine—Liver function test abnormal—Methotrexate—psoriasis	0.000285	0.00169	CcSEcCtD
Nimodipine—Depression—Prednisone—psoriasis	0.000284	0.00168	CcSEcCtD
Nimodipine—Hypertension—Mycophenolate mofetil—psoriasis	0.000284	0.00168	CcSEcCtD
Nimodipine—CACNA1F—Alzheimers Disease—TP53—psoriasis	0.00028	0.00816	CbGpPWpGaD
Nimodipine—Myalgia—Mycophenolate mofetil—psoriasis	0.00028	0.00165	CcSEcCtD
Nimodipine—AHR—Adipogenesis—PPARG—psoriasis	0.000279	0.00811	CbGpPWpGaD
Nimodipine—Diarrhoea—Hydroxyurea—psoriasis	0.000278	0.00164	CcSEcCtD
Nimodipine—CACNA1S—Alzheimers Disease—APOE—psoriasis	0.000276	0.00804	CbGpPWpGaD
Nimodipine—Oedema—Cyclosporine—psoriasis	0.000275	0.00162	CcSEcCtD
Nimodipine—NR3C2—Gene Expression—TARS—psoriasis	0.000273	0.00794	CbGpPWpGaD
Nimodipine—Nervous system disorder—Cyclosporine—psoriasis	0.00027	0.00159	CcSEcCtD
Nimodipine—Thrombocytopenia—Cyclosporine—psoriasis	0.000269	0.00159	CcSEcCtD
Nimodipine—Dizziness—Hydroxyurea—psoriasis	0.000268	0.00159	CcSEcCtD
Nimodipine—Oedema—Mycophenolate mofetil—psoriasis	0.000268	0.00159	CcSEcCtD
Nimodipine—Angiopathy—Dexamethasone—psoriasis	0.000267	0.00158	CcSEcCtD
Nimodipine—Angiopathy—Betamethasone—psoriasis	0.000267	0.00158	CcSEcCtD
Nimodipine—Hyperhidrosis—Cyclosporine—psoriasis	0.000266	0.00157	CcSEcCtD
Nimodipine—Hypertension—Prednisolone—psoriasis	0.000265	0.00156	CcSEcCtD
Nimodipine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000263	0.00155	CcSEcCtD
Nimodipine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000263	0.00155	CcSEcCtD
Nimodipine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000262	0.00155	CcSEcCtD
Nimodipine—Bradycardia—Prednisone—psoriasis	0.000261	0.00154	CcSEcCtD
Nimodipine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000259	0.00153	CcSEcCtD
Nimodipine—Hypertension—Hydrocortisone—psoriasis	0.000259	0.00153	CcSEcCtD
Nimodipine—Vomiting—Hydroxyurea—psoriasis	0.000258	0.00152	CcSEcCtD
Nimodipine—Rash—Hydroxyurea—psoriasis	0.000256	0.00151	CcSEcCtD
Nimodipine—Dermatitis—Hydroxyurea—psoriasis	0.000256	0.00151	CcSEcCtD
Nimodipine—Myalgia—Hydrocortisone—psoriasis	0.000255	0.00151	CcSEcCtD
Nimodipine—Headache—Hydroxyurea—psoriasis	0.000254	0.0015	CcSEcCtD
Nimodipine—Hypotension—Mycophenolate mofetil—psoriasis	0.000251	0.00148	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000251	0.00148	CcSEcCtD
Nimodipine—Oedema—Prednisolone—psoriasis	0.00025	0.00148	CcSEcCtD
Nimodipine—Dyspnoea—Cyclosporine—psoriasis	0.000245	0.00145	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000244	0.00144	CcSEcCtD
Nimodipine—Oedema—Hydrocortisone—psoriasis	0.000244	0.00144	CcSEcCtD
Nimodipine—Tachycardia—Prednisolone—psoriasis	0.000244	0.00144	CcSEcCtD
Nimodipine—Hypertension—Triamcinolone—psoriasis	0.000243	0.00144	CcSEcCtD
Nimodipine—Hyperhidrosis—Prednisolone—psoriasis	0.000242	0.00143	CcSEcCtD
Nimodipine—Nausea—Hydroxyurea—psoriasis	0.000241	0.00142	CcSEcCtD
Nimodipine—Pruritus—Mycophenolic acid—psoriasis	0.00024	0.00142	CcSEcCtD
Nimodipine—Myalgia—Triamcinolone—psoriasis	0.00024	0.00142	CcSEcCtD
Nimodipine—Nervous system disorder—Hydrocortisone—psoriasis	0.00024	0.00142	CcSEcCtD
Nimodipine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000239	0.00141	CcSEcCtD
Nimodipine—Tachycardia—Hydrocortisone—psoriasis	0.000239	0.00141	CcSEcCtD
Nimodipine—Depression—Methotrexate—psoriasis	0.000238	0.0014	CcSEcCtD
Nimodipine—Flushing—Prednisone—psoriasis	0.000238	0.0014	CcSEcCtD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000237	0.00691	CbGpPWpGaD
Nimodipine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000237	0.0014	CcSEcCtD
Nimodipine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000236	0.0014	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—CARM1—psoriasis	0.000234	0.00681	CbGpPWpGaD
Nimodipine—Diarrhoea—Mycophenolic acid—psoriasis	0.000233	0.00137	CcSEcCtD
Nimodipine—Angiopathy—Prednisone—psoriasis	0.000232	0.00137	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000232	0.00137	CcSEcCtD
Nimodipine—Immune system disorder—Prednisone—psoriasis	0.000231	0.00137	CcSEcCtD
Nimodipine—Oedema—Triamcinolone—psoriasis	0.00023	0.00136	CcSEcCtD
Nimodipine—Hypotension—Hydrocortisone—psoriasis	0.000228	0.00135	CcSEcCtD
Nimodipine—AHR—Circadian rythm related genes—LEP—psoriasis	0.000226	0.00657	CbGpPWpGaD
Nimodipine—Hepatobiliary disease—Methotrexate—psoriasis	0.000225	0.00133	CcSEcCtD
Nimodipine—Dizziness—Mycophenolic acid—psoriasis	0.000225	0.00133	CcSEcCtD
Nimodipine—Tachycardia—Triamcinolone—psoriasis	0.000225	0.00133	CcSEcCtD
Nimodipine—CACNA1D—Alzheimers Disease—APOE—psoriasis	0.000224	0.00652	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000223	0.00132	CcSEcCtD
Nimodipine—Hyperhidrosis—Triamcinolone—psoriasis	0.000222	0.00131	CcSEcCtD
Nimodipine—Hypertension—Dexamethasone—psoriasis	0.000221	0.00131	CcSEcCtD
Nimodipine—Hypertension—Betamethasone—psoriasis	0.000221	0.00131	CcSEcCtD
Nimodipine—Myalgia—Dexamethasone—psoriasis	0.000218	0.00129	CcSEcCtD
Nimodipine—Myalgia—Betamethasone—psoriasis	0.000218	0.00129	CcSEcCtD
Nimodipine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000216	0.0063	CbGpPWpGaD
Nimodipine—Vomiting—Mycophenolic acid—psoriasis	0.000216	0.00128	CcSEcCtD
Nimodipine—Rash—Mycophenolic acid—psoriasis	0.000214	0.00127	CcSEcCtD
Nimodipine—Dermatitis—Mycophenolic acid—psoriasis	0.000214	0.00127	CcSEcCtD
Nimodipine—Hepatitis—Methotrexate—psoriasis	0.000214	0.00126	CcSEcCtD
Nimodipine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000213	0.00622	CbGpPWpGaD
Nimodipine—Headache—Mycophenolic acid—psoriasis	0.000213	0.00126	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000211	0.00125	CcSEcCtD
Nimodipine—AHR—Circadian rythm related genes—NOS2—psoriasis	0.00021	0.00613	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00021	0.00124	CcSEcCtD
Nimodipine—Oedema—Dexamethasone—psoriasis	0.000209	0.00123	CcSEcCtD
Nimodipine—Oedema—Betamethasone—psoriasis	0.000209	0.00123	CcSEcCtD
Nimodipine—Anaemia—Prednisone—psoriasis	0.000206	0.00122	CcSEcCtD
Nimodipine—Dyspnoea—Triamcinolone—psoriasis	0.000205	0.00121	CcSEcCtD
Nimodipine—Nervous system disorder—Betamethasone—psoriasis	0.000205	0.00121	CcSEcCtD
Nimodipine—Nervous system disorder—Dexamethasone—psoriasis	0.000205	0.00121	CcSEcCtD
Nimodipine—Thrombocytopenia—Betamethasone—psoriasis	0.000204	0.00121	CcSEcCtD
Nimodipine—Thrombocytopenia—Dexamethasone—psoriasis	0.000204	0.00121	CcSEcCtD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—IL6—psoriasis	0.000204	0.00594	CbGpPWpGaD
Nimodipine—Tachycardia—Betamethasone—psoriasis	0.000204	0.0012	CcSEcCtD
Nimodipine—Tachycardia—Dexamethasone—psoriasis	0.000204	0.0012	CcSEcCtD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000204	0.00593	CbGpPWpGaD
Nimodipine—Hypersensitivity—Cyclosporine—psoriasis	0.000203	0.0012	CcSEcCtD
Nimodipine—Nausea—Mycophenolic acid—psoriasis	0.000202	0.00119	CcSEcCtD
Nimodipine—Hyperhidrosis—Dexamethasone—psoriasis	0.000202	0.00119	CcSEcCtD
Nimodipine—Hyperhidrosis—Betamethasone—psoriasis	0.000202	0.00119	CcSEcCtD
Nimodipine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.0002	0.00583	CbGpPWpGaD
Nimodipine—Cardiac disorder—Methotrexate—psoriasis	0.000199	0.00117	CcSEcCtD
Nimodipine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000198	0.00117	CcSEcCtD
Nimodipine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000198	0.00575	CbGpPWpGaD
Nimodipine—CACNA1C—Alzheimers Disease—APOE—psoriasis	0.000197	0.00573	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—PPARG—psoriasis	0.000197	0.00573	CbGpPWpGaD
Nimodipine—Hypotension—Betamethasone—psoriasis	0.000195	0.00115	CcSEcCtD
Nimodipine—Hypotension—Dexamethasone—psoriasis	0.000195	0.00115	CcSEcCtD
Nimodipine—Pruritus—Cyclosporine—psoriasis	0.000195	0.00115	CcSEcCtD
Nimodipine—Angiopathy—Methotrexate—psoriasis	0.000194	0.00115	CcSEcCtD
Nimodipine—Immune system disorder—Methotrexate—psoriasis	0.000193	0.00114	CcSEcCtD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000193	0.00561	CbGpPWpGaD
Nimodipine—Hypertension—Prednisone—psoriasis	0.000192	0.00114	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00019	0.00112	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00019	0.00112	CcSEcCtD
Nimodipine—Pruritus—Mycophenolate mofetil—psoriasis	0.00019	0.00112	CcSEcCtD
Nimodipine—Myalgia—Prednisone—psoriasis	0.00019	0.00112	CcSEcCtD
Nimodipine—Diarrhoea—Cyclosporine—psoriasis	0.000188	0.00111	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—CARM1—psoriasis	0.000187	0.00544	CbGpPWpGaD
Nimodipine—Hypersensitivity—Prednisolone—psoriasis	0.000184	0.00109	CcSEcCtD
Nimodipine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000184	0.00108	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—CARM1—psoriasis	0.000182	0.0053	CbGpPWpGaD
Nimodipine—Dizziness—Cyclosporine—psoriasis	0.000182	0.00107	CcSEcCtD
Nimodipine—Oedema—Prednisone—psoriasis	0.000182	0.00107	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Betamethasone—psoriasis	0.00018	0.00107	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00018	0.00107	CcSEcCtD
Nimodipine—Hypersensitivity—Hydrocortisone—psoriasis	0.00018	0.00106	CcSEcCtD
Nimodipine—CACNB3—Metabolism—NDUFA5—psoriasis	0.000179	0.00521	CbGpPWpGaD
Nimodipine—NR3C2—Generic Transcription Pathway—CARM1—psoriasis	0.000178	0.00519	CbGpPWpGaD
Nimodipine—Nervous system disorder—Prednisone—psoriasis	0.000178	0.00105	CcSEcCtD
Nimodipine—Tachycardia—Prednisone—psoriasis	0.000177	0.00105	CcSEcCtD
Nimodipine—Dizziness—Mycophenolate mofetil—psoriasis	0.000177	0.00105	CcSEcCtD
Nimodipine—Hyperhidrosis—Prednisone—psoriasis	0.000176	0.00104	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000175	0.00511	CbGpPWpGaD
Nimodipine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000175	0.00511	CbGpPWpGaD
Nimodipine—Vomiting—Cyclosporine—psoriasis	0.000175	0.00103	CcSEcCtD
Nimodipine—Rash—Cyclosporine—psoriasis	0.000173	0.00102	CcSEcCtD
Nimodipine—Dermatitis—Cyclosporine—psoriasis	0.000173	0.00102	CcSEcCtD
Nimodipine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000173	0.00504	CbGpPWpGaD
Nimodipine—Pruritus—Hydrocortisone—psoriasis	0.000173	0.00102	CcSEcCtD
Nimodipine—Headache—Cyclosporine—psoriasis	0.000172	0.00102	CcSEcCtD
Nimodipine—Anaemia—Methotrexate—psoriasis	0.000172	0.00102	CcSEcCtD
Nimodipine—AHR—Adipogenesis—STAT3—psoriasis	0.000171	0.00498	CbGpPWpGaD
Nimodipine—Vomiting—Mycophenolate mofetil—psoriasis	0.000171	0.00101	CcSEcCtD
Nimodipine—Hypersensitivity—Triamcinolone—psoriasis	0.00017	0.001	CcSEcCtD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000169	0.00493	CbGpPWpGaD
Nimodipine—Rash—Mycophenolate mofetil—psoriasis	0.000169	0.000999	CcSEcCtD
Nimodipine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000169	0.000999	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000169	0.00491	CbGpPWpGaD
Nimodipine—Headache—Mycophenolate mofetil—psoriasis	0.000168	0.000993	CcSEcCtD
Nimodipine—Diarrhoea—Hydrocortisone—psoriasis	0.000167	0.000988	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000166	0.000979	CcSEcCtD
Nimodipine—Dizziness—Prednisolone—psoriasis	0.000165	0.000978	CcSEcCtD
Nimodipine—Nausea—Cyclosporine—psoriasis	0.000163	0.000965	CcSEcCtD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—IL6—psoriasis	0.000163	0.00475	CbGpPWpGaD
Nimodipine—Pruritus—Triamcinolone—psoriasis	0.000163	0.000962	CcSEcCtD
Nimodipine—Dizziness—Hydrocortisone—psoriasis	0.000162	0.000955	CcSEcCtD
Nimodipine—Nausea—Mycophenolate mofetil—psoriasis	0.000159	0.000942	CcSEcCtD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—IL6—psoriasis	0.000159	0.00462	CbGpPWpGaD
Nimodipine—Myalgia—Methotrexate—psoriasis	0.000159	0.000937	CcSEcCtD
Nimodipine—Rash—Prednisolone—psoriasis	0.000158	0.000932	CcSEcCtD
Nimodipine—Dermatitis—Prednisolone—psoriasis	0.000158	0.000931	CcSEcCtD
Nimodipine—Headache—Prednisolone—psoriasis	0.000157	0.000926	CcSEcCtD
Nimodipine—Vomiting—Hydrocortisone—psoriasis	0.000155	0.000918	CcSEcCtD
Nimodipine—Rash—Hydrocortisone—psoriasis	0.000154	0.000911	CcSEcCtD
Nimodipine—Dermatitis—Hydrocortisone—psoriasis	0.000154	0.00091	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000153	0.00446	CbGpPWpGaD
Nimodipine—Headache—Hydrocortisone—psoriasis	0.000153	0.000905	CcSEcCtD
Nimodipine—CACNB3—Metabolism—CYP2S1—psoriasis	0.000152	0.00443	CbGpPWpGaD
Nimodipine—Dizziness—Triamcinolone—psoriasis	0.000152	0.000899	CcSEcCtD
Nimodipine—Nervous system disorder—Methotrexate—psoriasis	0.000149	0.000881	CcSEcCtD
Nimodipine—Thrombocytopenia—Methotrexate—psoriasis	0.000149	0.000879	CcSEcCtD
Nimodipine—Nausea—Prednisolone—psoriasis	0.000149	0.000878	CcSEcCtD
Nimodipine—AHR—Adipogenesis—TNF—psoriasis	0.000148	0.00431	CbGpPWpGaD
Nimodipine—Pruritus—Dexamethasone—psoriasis	0.000148	0.000873	CcSEcCtD
Nimodipine—Pruritus—Betamethasone—psoriasis	0.000148	0.000873	CcSEcCtD
Nimodipine—Hyperhidrosis—Methotrexate—psoriasis	0.000147	0.000868	CcSEcCtD
Nimodipine—Vomiting—Triamcinolone—psoriasis	0.000146	0.000865	CcSEcCtD
Nimodipine—Nausea—Hydrocortisone—psoriasis	0.000145	0.000858	CcSEcCtD
Nimodipine—Rash—Triamcinolone—psoriasis	0.000145	0.000857	CcSEcCtD
Nimodipine—Dermatitis—Triamcinolone—psoriasis	0.000145	0.000857	CcSEcCtD
Nimodipine—Headache—Triamcinolone—psoriasis	0.000144	0.000852	CcSEcCtD
Nimodipine—Diarrhoea—Dexamethasone—psoriasis	0.000143	0.000844	CcSEcCtD
Nimodipine—Diarrhoea—Betamethasone—psoriasis	0.000143	0.000844	CcSEcCtD
Nimodipine—Hypotension—Methotrexate—psoriasis	0.000142	0.000839	CcSEcCtD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	0.00014	0.00406	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—JUN—psoriasis	0.00014	0.00406	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000138	0.000818	CcSEcCtD
Nimodipine—Dizziness—Betamethasone—psoriasis	0.000138	0.000816	CcSEcCtD
Nimodipine—Dizziness—Dexamethasone—psoriasis	0.000138	0.000816	CcSEcCtD
Nimodipine—Nausea—Triamcinolone—psoriasis	0.000137	0.000808	CcSEcCtD
Nimodipine—Dyspnoea—Methotrexate—psoriasis	0.000135	0.000801	CcSEcCtD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	0.000134	0.00391	CbGpPWpGaD
Nimodipine—Hypersensitivity—Prednisone—psoriasis	0.000134	0.000792	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—CARM1—psoriasis	0.000133	0.00388	CbGpPWpGaD
Nimodipine—Vomiting—Dexamethasone—psoriasis	0.000133	0.000784	CcSEcCtD
Nimodipine—Vomiting—Betamethasone—psoriasis	0.000133	0.000784	CcSEcCtD
Nimodipine—Rash—Dexamethasone—psoriasis	0.000132	0.000778	CcSEcCtD
Nimodipine—Rash—Betamethasone—psoriasis	0.000132	0.000778	CcSEcCtD
Nimodipine—Dermatitis—Dexamethasone—psoriasis	0.000132	0.000777	CcSEcCtD
Nimodipine—Dermatitis—Betamethasone—psoriasis	0.000132	0.000777	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000131	0.000775	CcSEcCtD
Nimodipine—Headache—Betamethasone—psoriasis	0.000131	0.000773	CcSEcCtD
Nimodipine—Headache—Dexamethasone—psoriasis	0.000131	0.000773	CcSEcCtD
Nimodipine—Pruritus—Prednisone—psoriasis	0.000129	0.00076	CcSEcCtD
Nimodipine—CACNA1S—Alzheimers Disease—TNF—psoriasis	0.000128	0.00372	CbGpPWpGaD
Nimodipine—Diarrhoea—Prednisone—psoriasis	0.000124	0.000735	CcSEcCtD
Nimodipine—Nausea—Dexamethasone—psoriasis	0.000124	0.000733	CcSEcCtD
Nimodipine—Nausea—Betamethasone—psoriasis	0.000124	0.000733	CcSEcCtD
Nimodipine—Dizziness—Prednisone—psoriasis	0.00012	0.000711	CcSEcCtD
Nimodipine—CACNB4—Axon guidance—TYK2—psoriasis	0.00012	0.00348	CbGpPWpGaD
Nimodipine—AHR—Adipogenesis—IL6—psoriasis	0.000119	0.00348	CbGpPWpGaD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—IL6—psoriasis	0.000116	0.00338	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000116	0.00337	CbGpPWpGaD
Nimodipine—Vomiting—Prednisone—psoriasis	0.000116	0.000683	CcSEcCtD
Nimodipine—Rash—Prednisone—psoriasis	0.000115	0.000677	CcSEcCtD
Nimodipine—Dermatitis—Prednisone—psoriasis	0.000115	0.000677	CcSEcCtD
Nimodipine—CACNB2—Developmental Biology—CARM1—psoriasis	0.000114	0.00333	CbGpPWpGaD
Nimodipine—Headache—Prednisone—psoriasis	0.000114	0.000673	CcSEcCtD
Nimodipine—CACNA1S—Alzheimers Disease—TP53—psoriasis	0.000113	0.00328	CbGpPWpGaD
Nimodipine—Hypersensitivity—Methotrexate—psoriasis	0.000112	0.000662	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—LEP—psoriasis	0.000112	0.00325	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—NDUFA5—psoriasis	0.000109	0.00319	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—CARM1—psoriasis	0.000108	0.00315	CbGpPWpGaD
Nimodipine—Nausea—Prednisone—psoriasis	0.000108	0.000638	CcSEcCtD
Nimodipine—Pruritus—Methotrexate—psoriasis	0.000108	0.000635	CcSEcCtD
Nimodipine—NR3C2—Generic Transcription Pathway—VDR—psoriasis	0.000106	0.0031	CbGpPWpGaD
Nimodipine—Diarrhoea—Methotrexate—psoriasis	0.000104	0.000614	CcSEcCtD
Nimodipine—CACNA1D—Alzheimers Disease—TNF—psoriasis	0.000104	0.00302	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—NDUFA5—psoriasis	0.000104	0.00302	CbGpPWpGaD
Nimodipine—Dizziness—Methotrexate—psoriasis	0.0001	0.000594	CcSEcCtD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—IL6—psoriasis	9.96e-05	0.0029	CbGpPWpGaD
Nimodipine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.94e-05	0.00289	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—PPARG—psoriasis	9.74e-05	0.00283	CbGpPWpGaD
Nimodipine—Vomiting—Methotrexate—psoriasis	9.66e-05	0.000571	CcSEcCtD
Nimodipine—Rash—Methotrexate—psoriasis	9.58e-05	0.000566	CcSEcCtD
Nimodipine—Dermatitis—Methotrexate—psoriasis	9.57e-05	0.000566	CcSEcCtD
Nimodipine—CACNB3—Axon guidance—TYK2—psoriasis	9.56e-05	0.00278	CbGpPWpGaD
Nimodipine—Headache—Methotrexate—psoriasis	9.52e-05	0.000563	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—CARM1—psoriasis	9.51e-05	0.00277	CbGpPWpGaD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—IL6—psoriasis	9.43e-05	0.00275	CbGpPWpGaD
Nimodipine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.32e-05	0.00271	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CYP2S1—psoriasis	9.3e-05	0.00271	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—TYK2—psoriasis	9.3e-05	0.00271	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—TP53—psoriasis	9.21e-05	0.00268	CbGpPWpGaD
Nimodipine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.19e-05	0.00267	CbGpPWpGaD
Nimodipine—CACNA1D—Alzheimers Disease—TP53—psoriasis	9.14e-05	0.00266	CbGpPWpGaD
Nimodipine—CACNA1C—Alzheimers Disease—TNF—psoriasis	9.11e-05	0.00265	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—NDUFA5—psoriasis	9.1e-05	0.00265	CbGpPWpGaD
Nimodipine—Nausea—Methotrexate—psoriasis	9.03e-05	0.000533	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—LEP—psoriasis	8.94e-05	0.0026	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CYP2S1—psoriasis	8.81e-05	0.00257	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—LEP—psoriasis	8.69e-05	0.00253	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—CARM1—psoriasis	8.59e-05	0.0025	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—TYK2—psoriasis	8.53e-05	0.00248	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—VEGFA—psoriasis	8.46e-05	0.00246	CbGpPWpGaD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	8.43e-05	0.00246	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—IL6—psoriasis	8.43e-05	0.00245	CbGpPWpGaD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—IL6—psoriasis	8.29e-05	0.00241	CbGpPWpGaD
Nimodipine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.04e-05	0.00234	CbGpPWpGaD
Nimodipine—CACNA1C—Alzheimers Disease—TP53—psoriasis	8.03e-05	0.00234	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—PPARG—psoriasis	7.78e-05	0.00227	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CYP2S1—psoriasis	7.74e-05	0.00225	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—PPARG—psoriasis	7.57e-05	0.0022	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CARM1—psoriasis	7.44e-05	0.00217	CbGpPWpGaD
Nimodipine—NR3C2—Generic Transcription Pathway—PPARG—psoriasis	7.42e-05	0.00216	CbGpPWpGaD
Nimodipine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.93e-05	0.00202	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—TYK2—psoriasis	6.82e-05	0.00199	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—TYK2—psoriasis	6.81e-05	0.00198	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—VEGFA—psoriasis	6.76e-05	0.00197	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—NFKB1—psoriasis	6.65e-05	0.00194	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—TYK2—psoriasis	6.64e-05	0.00193	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—VEGFA—psoriasis	6.58e-05	0.00191	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—LEP—psoriasis	6.37e-05	0.00185	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—VEGFA—psoriasis	6.03e-05	0.00176	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—STAT3—psoriasis	5.97e-05	0.00174	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—IL6—psoriasis	5.85e-05	0.0017	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—TYK2—psoriasis	5.84e-05	0.0017	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—PPARG—psoriasis	5.55e-05	0.00161	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—TYK2—psoriasis	5.53e-05	0.00161	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—LEP—psoriasis	5.46e-05	0.00159	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—NFKB1—psoriasis	5.31e-05	0.00155	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—TNF—psoriasis	5.17e-05	0.00151	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—NFKB1—psoriasis	5.17e-05	0.00151	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—LEP—psoriasis	5.17e-05	0.00151	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—VDR—psoriasis	5.13e-05	0.00149	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—TYK2—psoriasis	4.86e-05	0.00142	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—TYK2—psoriasis	4.86e-05	0.00141	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—VEGFA—psoriasis	4.82e-05	0.0014	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—VEGFA—psoriasis	4.82e-05	0.0014	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—STAT3—psoriasis	4.78e-05	0.00139	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—PPARG—psoriasis	4.76e-05	0.00138	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—VEGFA—psoriasis	4.69e-05	0.00137	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—IL6—psoriasis	4.67e-05	0.00136	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—STAT3—psoriasis	4.65e-05	0.00135	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CAT—psoriasis	4.57e-05	0.00133	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—IL6—psoriasis	4.55e-05	0.00132	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CARM1—psoriasis	4.54e-05	0.00132	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—LEP—psoriasis	4.54e-05	0.00132	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—PPARG—psoriasis	4.5e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CARM1—psoriasis	4.3e-05	0.00125	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—IL6—psoriasis	4.17e-05	0.00121	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—TYK2—psoriasis	4.17e-05	0.00121	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—TNF—psoriasis	4.13e-05	0.0012	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—VEGFA—psoriasis	4.13e-05	0.0012	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—NDUFA5—psoriasis	4.03e-05	0.00117	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—TNF—psoriasis	4.02e-05	0.00117	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—PPARG—psoriasis	3.96e-05	0.00115	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—TYK2—psoriasis	3.95e-05	0.00115	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—VEGFA—psoriasis	3.91e-05	0.00114	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—NFKB1—psoriasis	3.79e-05	0.0011	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CARM1—psoriasis	3.78e-05	0.0011	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—PPARG—psoriasis	3.57e-05	0.00104	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—APOE—psoriasis	3.55e-05	0.00103	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—TYK2—psoriasis	3.47e-05	0.00101	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—VEGFA—psoriasis	3.44e-05	0.001	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—VEGFA—psoriasis	3.44e-05	0.001	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CYP2S1—psoriasis	3.43e-05	0.000998	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—STAT3—psoriasis	3.4e-05	0.000991	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—IL6—psoriasis	3.34e-05	0.000971	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—IL6—psoriasis	3.33e-05	0.00097	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—NFKB1—psoriasis	3.25e-05	0.000945	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—IL6—psoriasis	3.25e-05	0.000945	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PPARG—psoriasis	3.1e-05	0.000901	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—NFKB1—psoriasis	3.07e-05	0.000895	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—VEGFA—psoriasis	2.95e-05	0.000858	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—TNF—psoriasis	2.95e-05	0.000858	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—STAT3—psoriasis	2.92e-05	0.000849	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—IL6—psoriasis	2.86e-05	0.000831	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CAT—psoriasis	2.79e-05	0.000814	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—VEGFA—psoriasis	2.79e-05	0.000812	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—STAT3—psoriasis	2.76e-05	0.000804	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—IL6—psoriasis	2.7e-05	0.000787	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—NFKB1—psoriasis	2.7e-05	0.000787	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CAT—psoriasis	2.65e-05	0.000771	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—TNF—psoriasis	2.53e-05	0.000735	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—VEGFA—psoriasis	2.45e-05	0.000714	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—STAT3—psoriasis	2.43e-05	0.000707	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—TNF—psoriasis	2.39e-05	0.000696	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—IL6—psoriasis	2.38e-05	0.000692	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—IL6—psoriasis	2.38e-05	0.000692	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CAT—psoriasis	2.33e-05	0.000677	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—APOE—psoriasis	2.17e-05	0.000632	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—TNF—psoriasis	2.1e-05	0.000612	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—APOE—psoriasis	2.06e-05	0.000599	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—IL6—psoriasis	2.04e-05	0.000593	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—IL6—psoriasis	1.93e-05	0.000562	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PPARG—psoriasis	1.89e-05	0.000551	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.87e-05	0.000546	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—APOE—psoriasis	1.81e-05	0.000526	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PPARG—psoriasis	1.79e-05	0.000521	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—IL6—psoriasis	1.7e-05	0.000494	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CARM1—psoriasis	1.67e-05	0.000487	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000464	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PPARG—psoriasis	1.57e-05	0.000458	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CAT—psoriasis	1.03e-05	0.0003	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—APOE—psoriasis	8e-06	0.000233	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CARM1—psoriasis	7.78e-06	0.000227	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PPARG—psoriasis	6.97e-06	0.000203	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CAT—psoriasis	4.79e-06	0.000139	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—APOE—psoriasis	3.72e-06	0.000108	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PPARG—psoriasis	3.24e-06	9.43e-05	CbGpPWpGaD
